Protein kinase C-η controls CTLA-4–mediated regulatory T cell function-Reference-Cited by-同舟云学术

Protein kinase C-η controls CTLA-4–mediated regulatory T cell function

Published:2014-04-06 Issue:5 Volume:15 Page:465-472
ISSN:1529-2908
Container-title:Nature Immunology
language:en
Short-container-title:Nat Immunol

Author:

Kong Kok-Fai,Fu Guo,Zhang Yaoyang,Yokosuka Tadashi,Casas Javier,Canonigo-Balancio Ann J,Becart Stephane,Kim Gisen,Yates John R,Kronenberg Mitchell,Saito Takashi,Gascoigne Nicholas R J^ORCID,Altman Amnon

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/ni.2866.pdf

Reference51 articles.

1. Bennett, C.L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20–21 (2001).

2. Fontenot, J.D., Gavin, M.A. & Rudensky, A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330–336 (2003).

3. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057–1061 (2003).

4. Zanin-Zhorov, A. et al. Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 328, 372–376 (2010).

5. Collins, A.V. et al. The interaction properties of costimulatory molecules revisited. Immunity 17, 201–210 (2002).

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability;Acta Pharmaceutica Sinica B;2024-08

2. Immunological Assessment of Key Biomarkers in Stage III Breast Cancer;Journal of Contemporary Medical Sciences;2024-07-02

3. Mechanistic Insights into the Inhibition of a Common CTLA-4 Gene Mutation in the Cytoplasmic Domain;Molecules;2024-03-16

4. Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets;Frontiers in Immunology;2024-03-15

5. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy;Cell Death & Disease;2024-01-08